![]() ![]() Ohlstein EH, Brooks DP, Feuerstein GZ, Ruffolo RR: Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Hypertension 1997, 30:240–246.īlum RA, Kazierad DJ, Tenero DM: A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies. Price DA, De‘Oliveira JM, Fisher NDL, Hollenberg NK: Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Philadelphia: WB Saunders 2000:621–637.Įdwards RM, Aiyer N, Chilstein EH, et al.: Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist SK& F 108566. In Hypertension: a Companion to Brenner and Rector‘s The Kidney. Ruddy MC, Kostis JB: Angiotensin II receptor antagonist. Gavras I, Gavras H: Effects of eprosartan versus enalapril in hypertensive patients in the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, doubleblind, multicenter study. Evidence from comparative pharmacological interruption of the renin system. Hollenberg NK, Fisher NDL, Price DA: Pathways for angiotensin II generation in intact human tissue. ![]() The Heart Outcome Prevention Evaluation (HOPE) Study Investigators: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high risk patients. If research already under way supports these early suggestions, then eprosartan will be an important addition to our therapeutic armamentarium.īurnier M, Brunner HR: Angiotensin II receptor antagonists. Eprosartan doses well below those required for control of blood pressure have a pronounced effect on the kidney. One such example pertains to the difference in the doseresponse relationship for the action of eprosartan on the renal blood supply in comparison with other AT 1 blockers. The reduction in catecholamine release induced by eprosartan that has been observed in animal models may account for some special examples of increased efficacy. This feature may prove to be useful for titration in the fragile patient. It differs functionally in vitro in being a pure competitive antagonist, as opposed to the nonequilibrium, insurmountable characteristics of the other blockers. Does eprosartan have a special role within this class? Eprosartan differs structurally from the other AT 1 blockers in that it is not a biphenyl tetrazole. The AT 1 blocker class is growing rapidly, at least in part because many believe that these drugs will share with the ACE inhibitors the special ability to reduce morbidity and mortality. These agents, including eprosartan, are extraordinarily well tolerated, not only when compared with antihypertensive agents but also in comparison with the ACE inhibitors, which are rather well tolerated. The advent of angiotensin II receptor 1 (AT 1) blockers has created new opportunities. When angiotensin-converting enzyme (ACE) inhibition first became available to block the renin system, few could have predicted the evolution that would occur in this field. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |